


# Computational Modeling Work in Targeted Pulmonary Drug Delivery

Yu FENG, Ph.D.




Assistant Professor  
School of Chemical Engineering  
Oklahoma State University, Stillwater, OK, USA

E-mail: [yu.feng@okstate.edu](mailto:yu.feng@okstate.edu)

Website: <http://www.cbb-okstate.com>

# Motivations

- **Animal Studies and Clinical Studies**
  - Invasive
  - Expensive
  - Long Research Cycle
  - Imaging Resolution Limitations
- **Alternative Methods**
  - *In-Silico* Studies based on the Natural Laws of Physics



# Targeted Pulmonary Drug Delivery

- **Background**


- Pulmonary Drug Delivery Advantages
- Low Efficiency Induced Side-effects

- **Goal**

- Higher regional deposition efficiency
- Reduced side-effects

- **Preliminary Study Implications**

- Low inhalation flow rate
- Refined release position



# Governing Equations (Euler-Lagrange)


- **Primary Phase (Airflow)**

$$\frac{\partial \rho}{\partial t} + \frac{\partial(\rho u_j)}{\partial x_j} = 0$$


$$\frac{\partial(\rho u_i)}{\partial t} + \frac{\partial(\rho u_i u_j)}{\partial x_j} = -\frac{\partial p}{\partial x_i} + \frac{\partial \tau_{ij}}{\partial x_j} + g_i$$

- **Secondary Phase (Pulmonary Drug Particles)**


$$\frac{d}{dt}(m_p u_i^p) == F_i^D + F_i^L + F_i^{BM} + F_i^G$$





# Conventional Pulmonary Drug Delivery



Drug Particle Release Map  
 $Q_{in}=1$  L/min  $d_p=1$  micron




⊕ Drug Release Position







# Targeted Pulmonary Drug Delivery (Left Upper Lobe)




Drug Particle Release Map  
 $Q_{in}=1$  L/min  $d_p=1$  micron


 Drug Release Position




# Targeted Pulmonary Drug Delivery (Right Lower Lobe)



Drug Particle Release Map  
 $Q_{in}=1$  L/min  $d_p=1$  micron



 Drug Release Position





# Challenges and Future Directions


- **Intersubject Variability Study**
  - CFPD Simulation Results with Error Bars
- **Next-Generation Inhaler Design**
  - Low Actuation Flow Rate
- **Precise Treatment Plan**
  - Fast and Accurate
  - Big Data and Machine Learning



# Intersubject Variability Study




# Bring the Simulation to Health Endpoints



# Thank you for your attention!

**PI: Yu FENG, Ph.D.**



Assistant Professor  
School of Chemical Engineering  
Oklahoma State University, Stillwater, OK, USA

**E-mail:** [yu.feng@okstate.edu](mailto:yu.feng@okstate.edu)

**Website:** <http://www.cbb@okstate.com>